Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of DXC006 combined with immune checkpoint inhibitor or platinum in small cell lung cancer
CTR20261618Phase 2Active
- Sponsor
- Hangzhou DAC Biotech
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DXC-006 in small cell lung cancer (SCLC), sponsored by Hangzhou DAC Biotech. Started Aug 2026; status: active.
02
Drugs
DXC-006
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20261618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261618.